MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Seasonal Allergies

Treatments: Drug: MK0524

Study type: Interventional

Funder types: Industry

Identifiers

NCT00533208

2007_616

0524-005

Details and patient eligibility

About

To assess the efficacy of MK0524 on seasonal allergies.

Enrollment: 766 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Person has had at least 2 years of seasonal allergies
• Person has had a positive skin test to at least 1 of the allergens of the season
• Person is a non-smoker

Exclusion criteria

• Person has been hospitalized within the last 4 weeks
• Person is a female who has had a baby within the last 8 weeks or is still breast-feeding

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind